Investors

Financial Communications Schedule for the First Half of 2017

26 January 2017

Press Release – For immediate release  – January 26, 2017 – 17:45 CET – Sophia Antipolis, France

Median Technologies (ALMDT.PA), the Imaging Phenomics™ Company, announces the publication date for its 2016 results:

Publication Date
2016 Results April 12, 2017*

*Distribution after the close of trading

About Median Technologies

alternext_almdt_modifiedMedian Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics™ to provide insights into novel therapies and treatment strategies. Our unique solutions, LMS for lesion management and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need, with an eye on reducing overall care costs. This is how we are helping to create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a US subsidiary in Boston, Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA-PME SME equity savings plan setup and has received the label Pass French Tech Promotion 2016-2017. More information: www.mediantechnologies.com

peapmelogo-pass-frt-a-promo2016-2017

 

 

 

 

Contacts

MEDIAN Technologies

Fredrik Brag
CEO
+33 4 92 90 65 82
fredrik.brag@mediantechnologies.com

Actifin (Investors)

Ghislaine Gasparetto
+33 1 56 88 11 11
ggasparetto@actifin.fr

Alizé RP (Press)

Caroline Carmagnol
Wendy Rigal

+33 1 44 54 36 66
median@alizerp.com

 

Cookies help us deliver our services. By using our services, you agree to our use of cookies.